Arthritis Today—January 25, 2013
The U.S. Food and Drug Administration (FDA) has proposed new rules that would require makers of metal-on-metal hip-replacement implants to either prove their products are safe or stop selling them. Serious problems associated with the all-metal implants – including high early failure rates and the shedding of microscopic metal particles in the body – have led to calls for stricter regulation of the devices.
Under the proposed rules, manufacturers would have 90 days to submit data showing that an implant is safe and effective. All-metal implants that don’t meet these requirements would be removed from the market.
Manufacturers, the public and others can weigh in on the proposals during a 90-day comment period, followed by FDA review of the feedback before the rules are finalized – a process the FDA estimates will take about a year.
Medical devices receive FDA approval in one of two ways. Devices considered high risk must be tested in human clinical trials to prove their safety and effectiveness. But for other devices, clinical testing can, and often is, waived if manufacturers can prove that their new device is roughly similar to one already in use – a fast-track process known as 510(k) clearance. Metal-on-metal hips – those with a ball and socket made of an alloy that includes chromium and cobalt – were approved via the 510(k) route.
Timothy Wright, PhD, a biomechanical engineering expert at Hospital for Special Surgery in New York, says the troubled history of all-metal hips highlights the flaws in the 510(k) clearance process. “It didn’t start out that way, but [the 510(k) process] has become a huge pipeline for [untested] devices to get on the market through the similar-equivalence route,” he says.
Many all-metal hips had serious problems from the start, including high early failure rates. Designed to last longer than other implants, they have been shown in international studies to wear out sooner – in some cases, much sooner, especially in women and in patients with larger implants. Compared with other implants, all-metal hip replacement failure rates at seven years are about three times higher in women and two times higher in men.
Other problems associated with all-metal implants are caused by cobalt and/or chromium ions – minute particles produced when metal parts rub together. The ions can trigger inflammation that destroys tissue and bone in the hip joint, resulting in severe damage and long-term disability for some patients.
Metal ions can also enter the bloodstream and circulate throughout the body, and they can damage the heart and brain. There is no consensus about how much metal in the bloodstream is harmful, and the FDA has said it does not have enough data to specify a dangerous blood-ion level.
“The FDA is correct in saying that there is no level above which we should be concerned and below which we shouldn’t have to worry,” Wright says. “Internal data at [Hospital for Special Surgery] show that some patients can have a high ion level and not have any problems, whereas others with a low level can have problems. So although it’s true that elevated blood levels of ions indicate that metal debris is showing up in the blood, that’s just one piece of the puzzle.”
In an effort to fit some of the puzzle pieces together, the FDA issued a safety communication in conjunction with the proposed rule change. It details the unique risks of all-metal implants and makes recommendations for monitoring the estimated 500,000 patients in the United States who have them.
The communication advises annual monitoring with a physical exam and routine X-rays for asymptomatic patients. More frequent follow-up is suggested for those at higher risk, such as women and patients who take corticosteroids or are overweight. Patients with adverse reactions, such as joint pain or swelling, should have imaging and blood ion tests every six months.
Wright agrees. He notes that studies show a significant number of asymptomatic patients – about 30 percent – have the beginnings of adverse tissue reactions. “So the message is, even if you’re feeling fine, the best thing to do is have a conversation with your clinician and come up with a plan for how often you should be followed. Complications such as tissue damage and implant loosening can be severe, and there should be a plan in place,” he says.
Wright points out that although the FDA’s move seems late in coming, the agency began asking manufacturers to start collecting data on patient outcomes as soon as reports of problems with the implants began to surface.
“Here was a device that looked concerning, but at first no one knew the scope of the problem,” says Wright, adding that the data-gathering process by the manufacturers took too long. “So this current ratcheting up – asking for safety and effectiveness data – is in response to that.”
The full story originally appeared at arthritistoday.org.